pSivida to Present at the Ladenburg Thalmann 2017 Healthcare Conference
September 22 2017 - 2:29PM
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development
of sustained release drug products and technologies, today
announced that Nancy Lurker, President and Chief Executive Officer,
will be presenting at the Ladenburg Thalmann 2017 Healthcare
Conference on Tuesday, September 26, 2017 at 10:30
am (ET) at the Sofitel Hotel in New York, NY.
A live audio and/or webcast and subsequent
archived replay of pSivida’s presentations may be accessed via the
Investors section of the Company’s website under “Resources -
Events & Presentations” at www.psivida.com. The replay will be
available for 90 days after the event.
About pSivida
Corp.
pSivida Corp. (www.psivida.com), headquartered
in Watertown, MA, is a leader in the development of sustained
release drug products for treating eye diseases. pSivida has
developed three of only four FDA-approved sustained-release
treatments for back-of-the-eye diseases. The most recent, ILUVIEN®,
a micro-insert for diabetic macular edema, licensed to Alimera
Sciences, is currently sold directly in the U.S. and three EU
countries. Retisert®, an implant for posterior uveitis, is licensed
to and sold by Bausch & Lomb. pSivida's lead product candidate,
Durasert™ micro-insert for posterior segment uveitis, is being
independently developed. Two pivotal Phase 3 studies with Durasert
achieved their primary efficacy endpoint of prevention of
recurrence of uveitis at six months of follow-up with statistical
significance, and the Company plans to file an NDA by late December
2017/early January 2018. pSivida's pre-clinical development program
is focused on using its core platform technology Durasert™ to
deliver drugs to treat wet age-related macular degeneration,
glaucoma, osteoarthritis and other diseases. To learn more about
pSivida, please visit www.psivida.com and connect on Twitter,
LinkedIn, Facebook and Google+.
Contact:
EVC GroupMichael Polyviou/Doug
Sherk –
Investorsmpolyviou@evcgroup.com; dsherk@evcgroup.com212.850.6020;
646-445-4800
Thomas Gibson –
Mediatom@tomgibsoncommunications.com201-476-0322
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Sep 2023 to Sep 2024